| Literature DB >> 24485896 |
Tiia Koho1, Minni R L Koivunen2, Sami Oikarinen3, Laura Kummola4, Selina Mäkinen1, Anssi J Mähönen1, Amirbabak Sioofy-Khojine3, Varpu Marjomäki5, Artur Kazmertsuk5, Ilkka Junttila4, Markku S Kulomaa1, Heikki Hyöty6, Vesa P Hytönen7, Olli H Laitinen8.
Abstract
Coxsackievirus B3 (CVB3) is an important cause of acute and chronic viral myocarditis, and dilated cardiomyopathy (DCM). Although vaccination against CVB3 could significantly reduce the incidence of serious or fatal viral myocarditis and various other diseases associated with CVB3 infection, there is currently no vaccine or therapeutic reagent in clinical use. In this study, we contributed towards the development of a CVB3 vaccine by establishing an efficient and scalable ion exchange chromatography-based purification method for CVB3 virus and baculovirus-insect cell-expressed CVB3 virus-like particles (VLPs). This purification system is especially relevant for vaccine development and production on an industrial scale. The produced VLPs were characterized using a number of biophysical methods and exhibited excellent quality and high purity. Immunization of mice with VLPs elicited a strong immune response, demonstrating the excellent vaccine potential of these VLPs.Entities:
Keywords: CVB3; Ion exchange chromatography; VLP
Mesh：
Substances：
Year: 2014 PMID： 24485896 DOI： 10.1016/j.antiviral.2014.01.013
Source DB: PubMed Journal: Antiviral Res ISSN： 0166-3542 Impact factor: 5.970